vTv Therapeutics
VTVT
36 hedge funds and large institutions have $29.1M invested in vTv Therapeutics in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 4 closing their positions.
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
19% more capital invested
Capital invested by funds: $24.4M → $29.1M (+$4.7M)
3% more funds holding
Funds holding: 35 → 36 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.2M |
| 2 |
Renaissance Technologies
New York
|
+$295K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$184K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$112K |
| 5 |
Morgan Stanley
New York
|
+$79.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PSC
Piper Sandler & Co
Minneapolis,
Minnesota
|
-$1.56M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$491K |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$423K |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$314K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$92.7K |
VTVT Hedge Fund Activity: Q3 2016 in Review
36 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q3 2016, worth a combined $29.1M — up 19% from $24.4M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new VTVT positions and 4 closed out — a net gain of 1 holder — while 11 added to existing stakes and 6 trimmed.
The largest buyer was Sphera Funds Management, opening a new position worth an estimated $1.2M. The largest seller was Piper Sandler & Co, cutting an estimated $1.56M.
- 36 institutional investors held vTv Therapeutics (VTVT) as of Q3 2016, up from 35 in Q2 2016.
- Funds reported $29.1M of vTv Therapeutics stock for Q3 2016, up 19% quarter-over-quarter.
- 5 funds opened new vTv Therapeutics positions in Q3 2016 and 4 closed out, a net change of +1 holder.
- The largest vTv Therapeutics buyer in Q3 2016 was Sphera Funds Management, an estimated $1.2M added.
- The largest vTv Therapeutics seller in Q3 2016 was Piper Sandler & Co, an estimated $1.56M sold.
Based on aggregated 13F filings for Q3 2016.